Vexim is a specialist in the design and sale of minimally invasive solutions for the treatment of traumatic spine pathologies (low and high energy).

Based in Balma, near Toulouse, Vexim is an innovative company in the medical devices field, created and founded in 2006 by the investment fund Truffle Capital.

Vexim is a French start-up that has quickly gained recognition among leaders in its activity sector and one of the solutions developed by Vexim is a major innovation: SpineJack®. This innovative medical device treats vertebral fractures using minimally invasive surgery through an implant capable of returning a vertebra to its original shape and restoring spinal cord anatomy.

This medical device, which is based on cutting-edge technology, was envisioned both for the health benefits provided to patients and for its  practical nature and ease of use for clinicians:

Vexim has also developed Masterflow™, an integrated system for the mixing and injection of orthopaedic cement, improving the accuracy of and optimising the surgical procedure.
Vexim also sells two orthopaedic cements: Cohesion® Bone Cement and Interface™ Bone Fixation Composite.

From 2011, the figures speak for themselves on the success of Vexim:

• over 20,000 patients have been operated,

• 65 employees,

• 4 subsidiaries in Europe,

• 1 subsidiary in the United States,

• a number of distributors worldwide,

• 60% cumulative growth over 5 years,

• Eur 18.5 million turnover in 2016…

And Vexim’s ambition does not stop there as its CEO, Vincent Gardès, is determined to release SpineJack® on the US market in 2018, and seeks to capture 10% of the global market and attain a turnover of Eur 100 million within 5 years.

Vexim is backed financially by its shareholders: Truffle Capital, BPI (Banque Public d’Investissement), Kreaxi (formally Banexi Ventures Partners).